MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma

MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma

Abstract Osteosarcoma is the most prevalent primary bone malignancy in children and young adults. Resistance to chemotherapy remains a key challenge for effective treatment of patients with osteosarcoma. The aim of the present study was to investigate the preventive role of metallothionein-2A (MT2A)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Adèle Mangelinck, Maria Eugénia Marques da Costa, Bojana Stefanovska, Olivia Bawa, Mélanie Polrot, Nathalie Gaspar, Olivia Fromigué
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/22d185a0684f4e9a8d8e736977224818
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares